Hapten-carrier conjugates and uses thereof

Details Hapten-carrier conjugates and uses thereof Hapten-carrier conjugates and uses thereof

2005-05-10

2008-11-18

Mosher, Mary R. (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Conjugate or complex

C424S194100, C424S196110, C514S343000, C546S279400

Reexamination Certificate

active

07452541

ABSTRACT:
The present invention provides compositions comprising a conjugate of a hapten with a carrier in an ordered and repetitive array, and methods of making such compositions. The conjugates and compositions of the invention may comprise a variety of haptens, including hormones, toxins and drugs, especially drugs of addiction such as nicotine. Compositions and conjugates of the invention are useful for inducing immune responses against haptens, which can use useful in a variety of therapeutic, prophylactic and diagnostic regimens. In certain embodiments, immune responses generated using the conjugates, compositions and methods of the present invention are useful to prevent or treat addiction to drugs of abuse and the resultant diseases associated with drug addiction.

REFERENCES:
patent: 3819706 (1974-06-01), Mehta
patent: 3885046 (1975-05-01), Mehta
patent: 3888866 (1975-06-01), Leute et al.
patent: 4123431 (1978-10-01), Soffer et al.
patent: 4197237 (1980-04-01), Leute et al.
patent: 4722840 (1988-02-01), Valenzuela et al.
patent: 4788189 (1988-11-01), Glazer
patent: 4918166 (1990-04-01), Kingsman et al.
patent: 5071651 (1991-12-01), Sabara et al.
patent: 5143726 (1992-09-01), Thornton et al.
patent: 5256409 (1993-10-01), Blincko
patent: 5334394 (1994-08-01), Kossovsky et al.
patent: 5374426 (1994-12-01), Sabara et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5698424 (1997-12-01), Mastico et al.
patent: 5739026 (1998-04-01), Garoff et al.
patent: 5766602 (1998-06-01), Xiong et al.
patent: 5770380 (1998-06-01), Hamilton et al.
patent: 5789245 (1998-08-01), Dubensky, Jr. et al.
patent: 5792462 (1998-08-01), Johnston et al.
patent: 5814482 (1998-09-01), Dubensky, Jr. et al.
patent: 5871747 (1999-02-01), Gengoux-Sedlik et al.
patent: 5876727 (1999-03-01), Swain et al.
patent: 5928647 (1999-07-01), Rock
patent: 5939598 (1999-08-01), Kucherlapati et al.
patent: 6004763 (1999-12-01), Gengoux et al.
patent: 6054312 (2000-04-01), Larocca et al.
patent: 6231864 (2001-05-01), Birkett
patent: 6232082 (2001-05-01), Ennifar et al.
patent: 6380364 (2002-04-01), Mueller et al.
patent: 6699474 (2004-03-01), Cerny
patent: 6719978 (2004-04-01), Schiller et al.
patent: 6932971 (2005-08-01), Bachmann et al.
patent: 2002/0064529 (2002-05-01), Bohannon
patent: 2002/0064533 (2002-05-01), Murray
patent: 2002/0081295 (2002-06-01), Schiller et al.
patent: 2003/0157479 (2003-08-01), Bachmann et al.
patent: 2003/0175290 (2003-09-01), Renner et al.
patent: 2003/0175711 (2003-09-01), Renner et al.
patent: 2003/0219459 (2003-11-01), Bachmann et al.
patent: 2004/0033211 (2004-02-01), Bachmann et al.
patent: 2004/0076611 (2004-04-01), Bachmann et al.
patent: 2004/0076645 (2004-04-01), Bachmann et al.
patent: 2004/0136962 (2004-07-01), Renner et al.
patent: 2004/0141984 (2004-07-01), Bachmann et al.
patent: 0 259 149 (1993-12-01), None
patent: 0 576 357 (1993-12-01), None
patent: 0 385 610 (1994-03-01), None
patent: 0 465 081 (1994-04-01), None
patent: 0 283 505 (1994-07-01), None
patent: 0 425 082 (1995-04-01), None
patent: 0 656 354 (1995-06-01), None
patent: 2695563 (1994-03-01), None
patent: WO 92/03163 (1992-03-01), None
patent: WO 92/11291 (1992-07-01), None
patent: WO 92/13081 (1992-08-01), None
patent: WO 92/21333 (1992-12-01), None
patent: WO 94/06472 (1994-03-01), None
patent: WO 94/15585 (1994-07-01), None
patent: WO 94/28888 (1994-12-01), None
patent: WO 96/02248 (1996-02-01), None
patent: WO 96/05293 (1996-02-01), None
patent: WO 96/30049 (1996-10-01), None
patent: WO 96/30049 (1996-10-01), None
patent: WO 96/30523 (1996-10-01), None
patent: WO 97/31948 (1997-09-01), None
patent: WO 98/14216 (1998-04-01), None
patent: WO 98/15631 (1998-04-01), None
patent: WO 99/07839 (1999-02-01), None
patent: WO 99/07839 (1999-02-01), None
patent: WO 99/17803 (1999-04-01), None
patent: WO 99/28478 (1999-06-01), None
patent: WO 99/40934 (1999-08-01), None
patent: WO 99/40934 (1999-08-01), None
patent: WO 99/57289 (1999-11-01), None
patent: WO 99/57289 (1999-11-01), None
patent: WO 99/61054 (1999-12-01), None
patent: WO 99/67293 (1999-12-01), None
patent: WO 00/00462 (2000-01-01), None
patent: WO 00/23955 (2000-04-01), None
patent: WO 00/32227 (2000-06-01), None
patent: WO 00/32227 (2000-06-01), None
patent: WO 00/50461 (2000-08-01), None
patent: WO 00/59928 (2000-10-01), None
patent: WO 01/12176 (2001-02-01), None
patent: WO 01/12176 (2001-02-01), None
patent: WO 01/62284 (2001-08-01), None
patent: WO 01/77158 (2001-10-01), None
patent: WO 01/85208 (2001-11-01), None
patent: WO 01/85208 (2001-11-01), None
patent: WO 02/14478 (2002-02-01), None
patent: WO 02/056905 (2002-07-01), None
patent: WO 02/058635 (2002-08-01), None
patent: WO 02/058635 (2002-08-01), None
patent: WO 03/040105 (2003-05-01), None
Pentel, et al. A Nicotine Conjugate Vaccine Reduces Nicotine Distribution to Brain and Attenuates Its Behavioral and Cardiovascular Effects in Rats. Pharmacol. Biochem Behavior 2000; 65(1):191-198.
Chackerian, et al. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective anutoantibodies. J Clin Invest. 2001; 108(3):415-423.
Abraham, J.M., et al., “An invertible element of DNA controls phase variation of type 1 fimbriae ofEscherichia coli,”Proc. Natl. Acad. Sci. USA 82:5724-5727, National Academy Press (1985).
Abraham, S.N., et al., “Glycerol-Induced Unraveling of the Tight Helical Conformation ofEscherichia coliType 1 Fimbriae,”J. Bacteriol. 174:5145-5148, American Society for Microbiology (1992).
Adhin, M.R., et al., “Nucleotide Sequence from the ssRNA Bacteriophage JP34 Resolves the Discrepancy between Serological and Biophysical Classification,”Virology 170:238-242, Academic Press, Inc. (1989).
Aguzzi, A., “Prion diseases, blood and the immune system: concerns and reality,”Haematologica85:3-10, Il Pensiero Scientifico Editore (Jan. 2000).
Ansel, K.M., et al., “In Vivo-activated CD4 T Cells Upregulate CXC Cheomkine Receptor 5 and Reprogram Their Response to Lymphoid Chemokines,”J. Exp. Med. 190:1123-1134, The Rockefeller University Press (1999).
Ansel, K.M., et al., “A chemokine-driven positive feedback loop organizes lymphoid follicles,”Nature 406:309-314, Nature Publishing Group (Jul. 2000).
Antonysamy, M.A., et al., “Evidence for a Role of IL-17 in Organ Allograft Rejection: IL-17 Promotes the Functional Differentiation of Dendritic Cell Progenitors,”J. Immunol. 162:577-584, The American Association of Immunologists (1999).
Arenberg, D.A., et al., “The murine CC chemokine, 6C-kine, inhibits tumor growth and angiogenesis in a human lung cancer SCID mouse model,”Cancer Immunol. Immunother. 49:587-592, Springer-Verlag (Jan. 2001).
Arnon, R., et al., “A mimotope peptide-based vaccine againstSchistosoma mansoni: synthesis and characterization,”Immunology 101:555-562, Blackwell Science, Ltd. (Dec. 2000).
Bachmann, M.F., and Zinkernagel, R.M., “The influence of virus structure on antibody responses and virus serotype formation,”Immunol. Today 17:553-558, Elsevier Science, Ltd. (1996).
Bachmann, M.F., and Zinkernagel, R.M., “Neutralizing Antiviral B Cell Responses,”Annu. Rev. Immunol. 15:235-270, Annual Reviews, Inc. (1997).
Bachmann, M.F., et al., “TRANCE, a Tumor Necrosis Factor Family Member Critical for CD40 Ligand-independent T Helper Cell Activation,”J. Exp. Med. 189:1025-1031, The Rockefeller University Press (1999).
Banerjee, R.R., and Lazar, M.A., “Dimerization of Resistin and Resistin-like Molecules Is Determined by a Single Cysteine,”J. Biol. Chem. 276:25970-25973, The American Society for Biochemistry and Molecular Biology, Inc. (Jul. 2001).
Bard, F. et al., “Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease,”Nat. Med. 6:916-919, Nature Publishing Company (Aug. 2000).
Bass, S., and Yang, M., “Expressing cloned genes inEscherichia coli,

Affiliated with

Also associated with

Rating

Hapten-carrier conjugates and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hapten-carrier conjugates and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hapten-carrier conjugates and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4050398